Institute of Medicine, Chung-Shan Medical University, Taichung, Taiwan, ROC.
Int J Mol Med. 2011 Jul;28(1):9-15. doi: 10.3892/ijmm.2011.670. Epub 2011 Apr 6.
In order to investigate the clinical value of ATPase family AAA domain containing 3A (ATAD3A), a potential anti-apoptotic factor in prostate cancer (PCa), immunohistochemistry was used to measure ATAD3A expression in pathological specimens from 86 Chinese patients and in 183 tissue-array samples from American patients. The effect of ATAD3A on the expression of prostate specific antigen (PSA) and drug resistance in PCa cell lines was determined by in vitro experiments. ATAD3A was detected in 74 of 86 (86.0%) Chinese specimens and in 145 of 183 (79.2%) American patient samples. No difference was found in ATAD3A expression between these two patient groups. In vitro, silencing of ATAD3A expression reduced PSA secretion and cisplatin resistance, suggesting that ATAD3A was associated with PSA secretion and drug resistance in PCa.
为了研究三磷酸腺苷酶家族 AAA 结构域包含蛋白 3A（ATAD3A）在前列腺癌（PCa）中的潜在抗凋亡作用的临床价值，我们采用免疫组织化学方法检测了 86 例中国患者的病理标本和 183 例美国患者的组织芯片样本中 ATAD3A 的表达情况。通过体外实验确定了 ATAD3A 对前列腺特异性抗原（PSA）和 PCa 细胞系耐药性的影响。在 86 例中国患者标本中有 74 例（86.0%）和 183 例美国患者标本中有 145 例（79.2%）检测到 ATAD3A。这两组患者的 ATAD3A 表达无差异。体外实验结果显示，沉默 ATAD3A 表达可降低 PSA 分泌和顺铂耐药性，提示 ATAD3A 与 PCa 中的 PSA 分泌和耐药性有关。
